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Abst ract :  A short and efficient synthesis of novel benzo[c]quinolizin-3-one derivatives is described. The 
synthesis based on the tandem Mannich-Michael cyclization between 2-silyloxy-l,3-butadienes and a N-t-Boc 
iminium ion. The prepared erivatives are selective inhibitors of human steroid 5c~-reductase i oenzyme 1, thus 
having potential application as drugs for treatment of male pattern baldness and other DHT-dependent skin 
disorders. © 1998 Elsevier Science Ltd. All rights reserved. 
Steroid 5ct-reductase is a family of two isozymes, named type 1 (5ctR-l) and type 2 (5~R-2), that 
catalyzes the NADPH-dependent reduction of testosterone (T) to dihydrotestosterone (DHT), and other 3-oxo- 
4-ene steroids (e.g., progesterone, corticosterone, etc.) to the corresponding 5ct compounds. The 5cc-reductase 
and its product DHT play an important role in the pathogenesis of some important human diseases, i.e. benign 
prostatic hyperplasia (BHP) and prostatic ancer, and skin disorders uch as acne, alopecia, pattern baldness in 
men and hirsutism in women. Thus, the discovery of potent and selective inhibitors for the two isozymes 
appears of great importance for the pharmacological treatment of these pathologies.~ Although the precise role 
of each 5ctR isoenzyme in DHT-dependent diseases i  yet to be fully elucidated, however it is now clear that 
inhibitors of both enzymes are best applied to the BPH treatment, whilst selective inhibitors of 5czR-1 could 
potentially be used for skin disorders treatment. 
As part of our studies on 5tx-reductase 2 and its inhibitors 3 we discovered a series of 19-nor-10- 
azasteroids 1 (Figure 1) which were potent inhibitors of both human 5ctR isoenzymes. 4 
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In designing these inhibitors (Figure 1), the vinylogous amide was inserted into the steroid nucleus as 
substrate-like transition state mimic of the T to DHT conversion. 4'5 The presence of the nitrogen atom at 
position 10, conjugated with the carbonyl at C-3, is an essential feature for a good inhibition since, providing an 
increase of the negative partial charge on the oxygen, 4"5 it probably determines a strong interaction with an 
electrophilic residue in the enzyme active site. 
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Figure 1. 
Recently, some non-steroidal 5ctR inhibitors have been designed starting from the related parent steroidal 
inhibitors, and some of them have been found to be potent and selective 5cLR-1 inhibitors. ~ Selected examples 
of these non-steroidal inhibitors and their corresponding steroidal parents are shown in Figure 2. 
R1 R 2 
0 0 0 
I 
Me R Me H R RI 
2 3 4 5 
RI 
HOOC ~ HOOC 
6 7 
Figure 2. 
Thus, benzoquinoline derivatives (typified by compound 2) were derived from 4-azasteroids 3, 
phenantridine derivatives (typified by compound 4) from 6-azasteroids 5, and diene acids (typified by 
compound 6) from steroidal acrylates 7.1 
Prompted by these reports, we targeted two types of novel benzo[c]quinolizin-3-ones 8 and 9 (Figure 3) 
which, maintaining the typical enaminone moiety of 19-nor-10-azasteroids 1, are differentiated by the position 
of the conjugated C-C double bond. Compound 8, having the unsaturation atC-4 C-4a, belongs to the 1H- 
benzo[c]quinolizines series and was designed as a potential substrate-like transition state mimic, whereas 
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compound 9, of the 4aH-benzo[c]quinolizines series, was designed as a potential product-like transition state 
mimic. 
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F igure  3. 
We report herein on a short and efficient 4-step synthesis of novel benzo[c]quinolizine compounds 8 and 
9 (Scheme 1), and their inhibition against human recombinant 5ctR-1 and human prostate homogenates (which 
contain mainly the type 2 isoenzyme). 4 
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Scheme 1. 
Reagents and conditions: a) Boc20, Et3N, DMAP (cat.) CH2C12, 16 h, 25 °C; b) NaBI-I4 in EtOH, -25°C, 4 h; then HCI 2N 
in EtOH, pH 3-4, 0 °C, 1.5 h; c) Danishefsky's diene 14, Et3N, TMSOTfin CH2C12, 0--~ 25 °C, 30 min; then NaHCO3 (sat) 
36 h; d) 2-silyloxy-l,3-butadiene 15, Et3N, TMSOTfin CH2C12, 0~ 25 °C, 30 min; then NaHCO3 (sat) 36 h; e) Hg(OAc)2, 
EDTA tetrasodium salt, 5% CH3COOH (aq), 90 °C, 2 h. 
The dihydroquinolin-2-0ne 106 (commercially available) was protected as N-t-Boc, then reduced to the 
ethoxy derivative 12 by treatment with NaBH4 in EtOH at -25°C followed by the slow addition of HCI 2N up 
to pH 3-4, according to a reported method. 7 The key step of the synthesis was the Lewis acid catalyzed tandem 
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Mannich-Michael cyclization ofN-t-Boc iminium ion 13 with a silyloxydiene. The generation i situ of the N-t- 
Boc iminium ions from N-t-Boc et-ethoxy derivatives such as 12, can be promoted by different Lewis acid, s but 
in our hand the best choice was the use of TMSOTf according to the methodology reported by Pilli et al. 7 We 
have recently extended a similar strategy to an efficient short synthesis of 19-nor-10-azasteroids. 9 In the 
synthesis of the title compounds, the use of Danishefsky's diene 14 led directly to 4aH-benzo[c]quinolizin-3- 
one 9 in fair yield (30%). 1° Saturated compounds 16 was instead obtained by reaction of 13 with 2-silyloxy-l,3- 
butadiene 15 (prepared as reported tl or generated in situ from methyl vinyl ketone, TMSOTf and Et3N). The 
introduction of the double bond at the 4-4a position was achieved by Hg(OAc)2 oxidation,12 leading to target 
1H compound 8 in 20% yield, 1° besides a minor amount (ca. 10%) of the corresponding 4all  derivative 9. 
Compounds 8 and 9 were tested, in comparison with the know inhibitor finasteride, against human 
recombinant 5czR-1 and homogenates of human prostate according to reported procedures. 4"13 The resulting 
IC50 values (shown in Table 1) indicate that these compounds were selective inhibitors of 5ctR-1, with a 
potency dependent on the A-ring unsaturation, whereas no inhibition was observed against homogenates of
human prostate. This selectivity was instead not observed for the parent 19-nor-10-azasteroids: 4 for example, 
the most potent azasteroid 1, with R = I3-CONHBu t (Figure 1), was a dual inhibitor, displaying almost identical 
inhibition potency toward the two isoenzymes (Table 1). In analogy to the parent 19-nor-10-azasteroids, 
preliminary experiments shown that these benzo[c]quinolizinones w re reversible 5~x-R inhibitors. 
Table 1. Inhibition asainst Human 5cc-Reductase 1 and 2 
Compound Inhibition Ki (nM) Compound Inhibition IC50 (nM) 
5~R- 1 5(xR-2 5otR- 1 a 5(xR_2 b 
214 9 >1 000 $ 298 + 75 ni c 
415 920 20 000 9 5130 + 130 ni c 
616 1200 260 1 d 127 + 12 e 122 + 37 b 
Finasteride 911 + 85 1.2 _+ 0.25 
aDetermined . 13 No mhib~taon bserved up to a onrecombinant CHO cells, bDetermined onhuman prostate homogenates. 4 c . . . .  
10 ~ concentration f inhibitor. At this concentration the inhibition was 17% for 8 and 11% for 9. d9:1 mixture of A 9(1 l~ and A 8(9) 
isomers. R=I3-CONHBu t. e Determined on DU-145 cells. 
Of the two compounds, the best inhibitor was 2,3,5,6-tetrahydro-lH-benzo[c]quinolizin-3-one 8 which, if 
compared to the other non-steroidal inhibitors above mentioned (see Figure 2), seems to behave more similarly 
to compound 2 (LY266111) than to compound 4, which was a selective but weaker 5ctR-1 inhibitor, or 6, 
which was more potent against 5(xR-2 than 5c~R-1. As expected, in the same experiments finasteride was a 
more potent 5erR-2 inhibitor, but a weaker 5erR-1 inhibitor in comparison to 8. The inhibition potency of the 
4all derivative 9 was lower than that of IH derivative 8, in agreement with an analogous observation made on 
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19-nor-10-azasteroids. 4 The observed selective inhibition indicates a potential application of this new type of 
non-steroidal inhibitors as drugs for treatment of male pattern baldness and other DHT-dependent skin 
disorders.l Studies aimed at increasing the potency of these compounds by introducing different substituents on 
the benzo[c]quinolizin-3-one sk leton are in progress. 
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